BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OsteoBiologics Announces International Distribution Agreement For OBI's Cartilage And Bone Repair Products With ConMed Linvatec (CNMD)


10/19/2005 5:13:07 PM

SAN ANTONIO, Sept. 29 /PRNewswire/ -- OsteoBiologics, Inc. (OBI), an innovator in tissue repair technologies, announced today that it has signed an exclusive agreement providing for ConMed Linvatec to distribute OBI's cartilage and bone repair products for sports medicine and arthroscopy orthopedic procedures outside of the United States. ConMed Linvatec is a global leader in the fields of arthroscopy, multi-specialty endoscopic medical video systems and powered surgical instruments.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031002/OBILOGO )

OBI products are used in the reconstruction of the knee, shoulder, foot and ankle, hip and other joints. Under the terms of this agreement, OBI will retain distribution activities of its products in the U.S. and internationally in medical practice areas outside of sports medicine and arthroscopy orthopedic procedures. OBI cartilage and bone repair products in this agreement, subject to an initial evaluation period, include the TruFit(R) CB Plugs, TruKor(R) Instruments, TruGraft(TM) BGS Granules, TruGraft(TM) BGS Syringe and others.

OBI's proprietary PolyGraft(R) material technology provides the platform for all of its Tru(TM) brand resorbable scaffold products. It is unique in that it provides a biologically friendly and biomechanically stable scaffold during the time required for native tissue healing. The porous PolyGraft(R) material is composed of a patented blend of polylactide-co-glycolide, calcium sulfate and polyglycolide fibers which can be fabricated into products such as granules, blocks, wedges and other preformed shapes.

"ConMed Linvatec is a respected and recognized organization with a firm commitment to training and education. We believe that their experience, combined with OBI's products and technologies, will be very well received in the international marketplace," said Fred Dinger, President and CEO of OBI.

The announcement coincides with OBI's participation at the International Cartilage Repair Society's Surgical Skills Course in Vienna, Austria. The course is focused on cartilage repair treatments and the OBI TruFit(R) CB Plug will be one of the technologies presented as well as used during the hands-on lab portions of the meeting.

About OsteoBiologics, Inc.

OBI, located in San Antonio, Texas, is a private company that develops and manufactures bioabsorbable polymeric scaffolds, films, and related instrumentation for the repair and replacement of bone, soft tissue and articular cartilage. Its products are based on proprietary and patented technologies covered by U.S. and foreign patents. The PolyGraft(R) product and related scaffold formulations are protected under U.S. Patent Nos. 5,716,413, 6,511,511 and other patents pending.

The Company is focused on commercializing and further developing its platform technologies in arthroscopy and sports medicine. Additionally, OBI is actively forming strategic alliances with companies serving other areas of medicine such as spine, neurosurgery, trauma, general orthopedics, extremities, and wound care to leverage its technologies into those markets.

Certain statements made in this press release are forward looking statements as such term is defined in the Private Securities Litigation Reform Act of 1995.

For more information, please contact Daniel Lee, Director of Marketing, at (210) 690-2131.

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031002/OBILOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk,photodesk@prnewswire.comOsteoBiologics, Inc.

CONTACT: Daniel Lee, Director of Marketing of OsteoBiologics, Inc.,+1-210-690-2131, or daniel.lee@obi.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES